AT&T Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? AT&T Inc. trades at $22.3 (market cap $152.52B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: AT&T Inc. pays a 5.06% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, AT&T Inc. nearer its low. Which is the better fit depends on your goals.
| T | XBI | |
|---|---|---|
Market Cap | $152.52B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $29.62 | $164.28 |
52-Week Low | $20.49 | $85.16 |
Enterprise Value | $297.87B | — |
Dividend Yield | 5.06% | — |
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $22.26, up 2.13% with a bullish technical signal despite mixed moving averages. The stock shows strong fundamentals with a low P/E of 7.39, robust profitability margins (net margin 16.94%), and consistent earnings beats in recent quarters. Recent cash flow improvement to $15.12B in 2025 and declining debt-to-asset ratio to 32.59% in 2024 signal financial health. The company faces competitive pressures in telecom but benefits from fiber expansion and stable wireless pricing.
Outlook remains positive with analyst consensus target of $25.61 offering 15% upside. Key opportunities include dividend yield support and fiber growth, while risks involve intense telecom competition and potential earnings volatility. Wall Street sentiment is cautiously optimistic with 41% buy ratings, though technical indicators show some overbought conditions near-term.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →